Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts

Patrick Paulus, E. Richard Stanley, Romana Schäfer, Dietmar Abraham, Seyedhossein Aharinejad

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Overexpression of colony-stimulating factor-1 (CSF-1) and its receptor in breast cancer is correlated with poor prognosis. Based on the hypothesis that blockade of CSF-1 would be beneficial in breast cancer treatment, we developed a murinized, polyethylene glycol-linked antigen-binding fragment (Fab) against mouse (host) CSF-1 (anti-CSF-1 Fab). Mice bearing human, chemoresistant MCF-7 breast cancer xenografts were treated with combination chemotherapy (CMF: cyclophosphamide, methotrexate, 5-fluorouracil; cycled twice i.p.), anti-CSF-1 Fab (i.p., cycled every 3 days for 14 days), combined CMF and anti-CSF-1 Fab, or with Ringer's solution as a control. Anti-CSF-1 Fab alone suppressed tissue CSF-1 and retarded tumor growth by 40%. Importantly, in combination with CMF, anti-CSF-1 Fab reversed chemoresistance of MCF-7 xenografts, suppressing tumor development by 56%, down-regulating expression of the chemoresistance genes breast cancer-related protein, multidrug resistance gene 1, and glucosylceramide synthase, and prolonging survival significantly. Combined treatment also reduced angiogenesis and macrophage recruitment and down-regulated tumor matrix metalloproteinase-2 (MMP-2) and MMP-12 expression. These studies support the paradigm of CSF-1 blockade in the treatment of solid tumors and show that: anti-CSF-1 antibodies are potential therapeutic agents for the treatment of mammary cancer.

Original languageEnglish (US)
Pages (from-to)4349-4356
Number of pages8
JournalCancer Research
Volume66
Issue number8
DOIs
StatePublished - Apr 15 2006

Fingerprint

Macrophage Colony-Stimulating Factor
Heterografts
Breast Neoplasms
Antibodies
ceramide glucosyltransferase
Neoplasms
MDR Genes
Therapeutics
Immunoglobulin Fab Fragments
Matrix Metalloproteinase 2
Combination Drug Therapy
Matrix Metalloproteinases
Methotrexate
Fluorouracil
Cyclophosphamide
Macrophages

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. / Paulus, Patrick; Stanley, E. Richard; Schäfer, Romana; Abraham, Dietmar; Aharinejad, Seyedhossein.

In: Cancer Research, Vol. 66, No. 8, 15.04.2006, p. 4349-4356.

Research output: Contribution to journalArticle

Paulus, Patrick ; Stanley, E. Richard ; Schäfer, Romana ; Abraham, Dietmar ; Aharinejad, Seyedhossein. / Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. In: Cancer Research. 2006 ; Vol. 66, No. 8. pp. 4349-4356.
@article{f5f48fbb81d04c2f9022ffcb9c52e941,
title = "Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts",
abstract = "Overexpression of colony-stimulating factor-1 (CSF-1) and its receptor in breast cancer is correlated with poor prognosis. Based on the hypothesis that blockade of CSF-1 would be beneficial in breast cancer treatment, we developed a murinized, polyethylene glycol-linked antigen-binding fragment (Fab) against mouse (host) CSF-1 (anti-CSF-1 Fab). Mice bearing human, chemoresistant MCF-7 breast cancer xenografts were treated with combination chemotherapy (CMF: cyclophosphamide, methotrexate, 5-fluorouracil; cycled twice i.p.), anti-CSF-1 Fab (i.p., cycled every 3 days for 14 days), combined CMF and anti-CSF-1 Fab, or with Ringer's solution as a control. Anti-CSF-1 Fab alone suppressed tissue CSF-1 and retarded tumor growth by 40{\%}. Importantly, in combination with CMF, anti-CSF-1 Fab reversed chemoresistance of MCF-7 xenografts, suppressing tumor development by 56{\%}, down-regulating expression of the chemoresistance genes breast cancer-related protein, multidrug resistance gene 1, and glucosylceramide synthase, and prolonging survival significantly. Combined treatment also reduced angiogenesis and macrophage recruitment and down-regulated tumor matrix metalloproteinase-2 (MMP-2) and MMP-12 expression. These studies support the paradigm of CSF-1 blockade in the treatment of solid tumors and show that: anti-CSF-1 antibodies are potential therapeutic agents for the treatment of mammary cancer.",
author = "Patrick Paulus and Stanley, {E. Richard} and Romana Sch{\"a}fer and Dietmar Abraham and Seyedhossein Aharinejad",
year = "2006",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-05-3523",
language = "English (US)",
volume = "66",
pages = "4349--4356",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts

AU - Paulus, Patrick

AU - Stanley, E. Richard

AU - Schäfer, Romana

AU - Abraham, Dietmar

AU - Aharinejad, Seyedhossein

PY - 2006/4/15

Y1 - 2006/4/15

N2 - Overexpression of colony-stimulating factor-1 (CSF-1) and its receptor in breast cancer is correlated with poor prognosis. Based on the hypothesis that blockade of CSF-1 would be beneficial in breast cancer treatment, we developed a murinized, polyethylene glycol-linked antigen-binding fragment (Fab) against mouse (host) CSF-1 (anti-CSF-1 Fab). Mice bearing human, chemoresistant MCF-7 breast cancer xenografts were treated with combination chemotherapy (CMF: cyclophosphamide, methotrexate, 5-fluorouracil; cycled twice i.p.), anti-CSF-1 Fab (i.p., cycled every 3 days for 14 days), combined CMF and anti-CSF-1 Fab, or with Ringer's solution as a control. Anti-CSF-1 Fab alone suppressed tissue CSF-1 and retarded tumor growth by 40%. Importantly, in combination with CMF, anti-CSF-1 Fab reversed chemoresistance of MCF-7 xenografts, suppressing tumor development by 56%, down-regulating expression of the chemoresistance genes breast cancer-related protein, multidrug resistance gene 1, and glucosylceramide synthase, and prolonging survival significantly. Combined treatment also reduced angiogenesis and macrophage recruitment and down-regulated tumor matrix metalloproteinase-2 (MMP-2) and MMP-12 expression. These studies support the paradigm of CSF-1 blockade in the treatment of solid tumors and show that: anti-CSF-1 antibodies are potential therapeutic agents for the treatment of mammary cancer.

AB - Overexpression of colony-stimulating factor-1 (CSF-1) and its receptor in breast cancer is correlated with poor prognosis. Based on the hypothesis that blockade of CSF-1 would be beneficial in breast cancer treatment, we developed a murinized, polyethylene glycol-linked antigen-binding fragment (Fab) against mouse (host) CSF-1 (anti-CSF-1 Fab). Mice bearing human, chemoresistant MCF-7 breast cancer xenografts were treated with combination chemotherapy (CMF: cyclophosphamide, methotrexate, 5-fluorouracil; cycled twice i.p.), anti-CSF-1 Fab (i.p., cycled every 3 days for 14 days), combined CMF and anti-CSF-1 Fab, or with Ringer's solution as a control. Anti-CSF-1 Fab alone suppressed tissue CSF-1 and retarded tumor growth by 40%. Importantly, in combination with CMF, anti-CSF-1 Fab reversed chemoresistance of MCF-7 xenografts, suppressing tumor development by 56%, down-regulating expression of the chemoresistance genes breast cancer-related protein, multidrug resistance gene 1, and glucosylceramide synthase, and prolonging survival significantly. Combined treatment also reduced angiogenesis and macrophage recruitment and down-regulated tumor matrix metalloproteinase-2 (MMP-2) and MMP-12 expression. These studies support the paradigm of CSF-1 blockade in the treatment of solid tumors and show that: anti-CSF-1 antibodies are potential therapeutic agents for the treatment of mammary cancer.

UR - http://www.scopus.com/inward/record.url?scp=33646243569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646243569&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3523

DO - 10.1158/0008-5472.CAN-05-3523

M3 - Article

C2 - 16618760

AN - SCOPUS:33646243569

VL - 66

SP - 4349

EP - 4356

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -